UBS/CALL/ELI LILLY & CO/580/0.1/20.09.24 | Market Closed - Deutsche Boerse AG 13:25:57 2024-06-25 EDT | ||
| 31.16 EUR | +0.68% |
|
| Current month | +33.85% | ||
| 1 month | +37.27% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-25 | 31.16 | +0.68% |
| 24-06-24 | 30.95 | +3.27% |
| 24-06-21 | 29.97 | +0.07% |
| 24-06-20 | 29.95 | -1.80% |
| 24-06-19 | 30.5 | +2.14% |
Delayed Quote Deutsche Boerse AG
Last update June 25, 2024 at 01:25 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| WKN | UL78ZV |
| ISIN | CH1294722397 |
| Date issued | 2023-09-07 |
| Strike | 580 $ |
| Maturity | 2024-09-20 (87 Days) |
| Parity | 10 : 1 |
| Emission price | 6.15 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 31.63 € |
|---|---|
| Lowest since issue | 4.77 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
904.6
USD
Average target price
860.5
USD
Spread / Average Target
-4.87%
- Stock Market
- Warrants
- Warrant
